Efficacy of Super-Bioavailable Itraconazole and Conventional Itraconazole at Different Dosing Regimens in Glabrous Tinea Infection - A Randomized Clinical Trial

References

• Rengasamy M, Shenoy MM, Dogra S, et al. Indian Association of Dermatologists, Venereologists and Leprologists (IADVL) Task Force against Recalcitrant Tinea (ITART) Consensus on the Management of Glabrous Tinea (INTACT). Indian Dermatol Online J. 2020;11(4):502–519. doi:10.4103/idoj.IDOJ_233_20
   PubMedGoogle Scholar
• Bishnoi A, Vinay K, Dogra S. Emergence of recalcitrant dermatophytosis in India. Lancet Infect Dis. 2018;18(3):250–251. doi:10.1016/S1473-3099(18)30079-3
   PubMed Web of Science ®Google Scholar
• Verma SB, Zouboulis C. Indian irrational skin creams and steroid-modified dermatophytosis - an unholy nexus and alarming situation. J Eur Acad Dermatol Venereol. 2018;32(11):e426–e427. doi:10.1111/jdv.15025
   PubMed Web of Science ®Google Scholar
• Hay RJ, Ashbee HR. Fungal infections. In: Griffiths CE, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s Textbook of Dermatology. 9th ed. West Sussex: Wiley Blackwell; 2016:945.
   Google Scholar
• Schieke SM, Garg A. Fitzpatrick’s Dermatology in General Medicine. 8th ed. New York: The McGraw-Hill Companies; 2012:2294.
   Google Scholar
• Shenoy MM, Shenoy SM. Superficial fungal infections. In: Sacchidanand S, Oberoi C, Inamdar AC, editors. IADVL Textbook of Dermatology. 4th ed. Mumbai: Bhalani Publishing House; 2015:459–516.
   Google Scholar
• Khurana A, Sardana K, Chowdhary A. Antifungal resistance in dermatophytes: recent trends and therapeutic implications. Fungal Genet Biol. 2019;132(132):103255. doi:10.1016/j.fgb.2019.103255
   PubMedGoogle Scholar
• Khurana A, Agarwal A, Agrawal D, et al. Effect of different itraconazole dosing regimens on cure rates, treatment duration, safety, and relapse rates in adult patients with tinea corporis/cruris: a randomized clinical trial. JAMA Dermatol. 2022;158(11):1269–1278. doi:10.1001/jamadermatol.2022.3745
   PubMed Web of Science ®Google Scholar
• Das S, De A, Saha R, et al. The current Indian epidemic of dermatophytosis: a study on causative agents and sensitivity patterns. Indian J Dermatol. 2020;65(2):118–122. doi:10.4103/ijd.IJD_203_19
   PubMed Web of Science ®Google Scholar
• Lindsay J, Mudge S, Thompson GR. Effects of food and omeprazole on a novel formulation of super bioavailability itraconazole in healthy subjects. Antimicrob Agents Chemother. 2018;62(12):e01723–18. doi:10.1128/AAC.01723-18
   PubMed Web of Science ®Google Scholar
• Central Drugs Standard Control Organisation. Recommendations of the SEC (Antimicrobial & Antiviral) made in its 103nd meeting held on 25.08.2021 at CDSCO HQ, New Delhi. Available from: https://cdsco.gov.in/opencms/resources/UploadCDSCOWeb/2018/UploadCommitteeFiles/RecommendationSE%20Antimicrobial%20&%20Antiviral%2025.08.2021n.pdf. Accessed December 13, 2022.
   Google Scholar
• U.S. Food and Drug Administration. SPORANOX® (itraconazole) Capsules. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020083s040s041s044lbl.pdf. Accessed December 13, 2022.
   Google Scholar
• Singh SK, Subba N, Tilak R. Efficacy of terbinafine and itraconazole in different doses and in combination in the treatment of tinea infection: a randomized controlled parallel group open labeled trial with clinico-mycological correlation. Indian J Dermatol. 2020;65(4):284–289. doi:10.4103/ijd.IJD_548_19
   PubMed Web of Science ®Google Scholar
• Shenoy M, Dhoot D, Mahajan H, Barkate H. An open-label, randomized, double-arm clinical trial to compare the effectiveness and safety of super bioavailable itraconazole capsules and itraconazole capsules in the management of dermatophytosis in India. Clin Cosmet Investig Dermatol. 2021;Volume 14(14):1367–1376. doi:10.2147/CCID.S326642
   Google Scholar
• Mahajan H, Dhoot D, Deshmukh G, Barkate H. Comparative clinical effectiveness and safety of super bioavailable itraconazole and conventional itraconazole in management of dermatophytosis: a retrospective data analysis. Int J Res Dermatol. 2021;7(7):388–394. doi:10.18203/issn.2455-4529.IntJResDermatol20211427
   Google Scholar
• NHS Fife.DERMATOLOGY LIFE QUALITY INDEX (DLQI). Available from: https://www.nhsfife.org/media/32589/dermatology-life-quality-index-dlqi.pdf. Accessed December 13, 2022.
   Google Scholar
• Rajagopalan M, Inamadar A, Mittal A, et al. Expert Consensus on The Management of Dermatophytosis in India (ECTODERM India). BMC Dermatol. 2018;18(1):6. doi:10.1186/s12895-018-0073-1
   PubMed Web of Science ®Google Scholar
• Dhoot D, Jain GK, Manjhi M, Kesharwani P, Mahadkar N, Barkate H. Pharmacokinetic and clinical comparison of super-bioavailable itraconazole and conventional itraconazole at different dosing in dermatophytosis. Drugs Context. 2023;12:1. doi:10.7573/dic.2022-8-1
   Google Scholar
• Abuhelwa AY, Foster DJR, Mudge S, Hayes D, Upton RN. Population pharmacokinetic modeling of itraconazole and hydroxyl itraconazole for oral SUBA-itraconazole and Sporanox capsule formulations in healthy subjects in fed and fasted states. Antimicrob Agents Chemother. 2015;59(9):5681–5696. doi:10.1128/AAC.00973-15
   PubMed Web of Science ®Google Scholar
• Khurana A, Agarwal A, Singh A, et al. Predicting a therapeutic cut-off serum level of itraconazole in recalcitrant tinea corporis and cruris-A prospective trial. Mycoses. 2021;64(12):1480–1488. doi:10.1111/myc.13367
   PubMed Web of Science ®Google Scholar
• Hardin TC, Graybill JR, Fetchick R, Woestenborghs R, Rinaldi MG, Kuhn JG. Pharmacokinetics of itraconazole following oral administration to normal volunteers. Antimicrob Agents Chemother. 1988;32(9):1310–1313. doi:10.1128/AAC.32.9.1310
   PubMed Web of Science ®Google Scholar
• Mouton JW, van Peer A, de Beule K, Van Vliet A, Donnelly JP, Soons PA. Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. Antimicrob Agents Chemother. 2006;50(12):4096–4102. doi:10.1128/AAC.00630-06
   PubMed Web of Science ®Google Scholar
• Yun HY, Baek MS, Park IS, Choi BK, Kwon KI. Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. Eur J Clin Pharmacol. 2006;62(12):1033–1039. doi:10.1007/s00228-006-0200-5
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol. 1994;46(2):147–150. doi:10.1007/BF00199879
   PubMed Web of Science ®Google Scholar
• Zimmermann T, Yeates RA, Albrecht M, Laufen H, Wildfeuer A. Influence of concomitant food intake on the gastrointestinal absorption of fluconazole and itraconazole in Japanese subjects. Int J Clin Pharmacol Res. 1994;14(3):87–93.
   PubMedGoogle Scholar
• Bae SK, Park SJ, Shim EJ, et al. Increased oral bioavailability of itraconazole and its active metabolite, 7-hydroxyitraconazole, when coadministered with a vitamin C beverage in healthy participants. J Clin Pharmacol. 2011;51(3):444–451. doi:10.1177/0091270010365557
   PubMed Web of Science ®Google Scholar
• Rauseo AM, Mazi P, Lewis P, Burnett B, Mudge S, Spec A. Bioavailability of single-dose SUBA-itraconazole compared to conventional itraconazole under fasted and fed conditions. Antimicrob Agents Chemother. 2021;65(8):e0013421. doi:10.1128/AAC.00134-21
   PubMed Web of Science ®Google Scholar
• Sardana K, Khurana A, Singh A, Gautam RK. A pilot analysis of morphometric assessment of itraconazole brands using dermoscopy and its relevance in the current scenario. Indian Dermatol Online J. 2018;9(6):426–431. doi:10.4103/idoj.IDOJ_339_17
   PubMedGoogle Scholar
• Sardana K, Gupta A, Mathachan SR. Immunopathogenesis of dermatophytoses and factors leading to recalcitrant infections. Indian Dermatol Online J. 2021;12(3):389–399. doi:10.4103/idoj.IDOJ_503_20
   PubMedGoogle Scholar
• Cauwenbergh G, Degreef H, Heykants J, Woestenborghs R, Van Rooy P, Haeverans K. Pharmacokinetic profile of orally administered itraconazole in human skin. J AmAcad Dermatol. 1988;18(2):263–268. doi:10.1016/S0190-9622(88)70037-7
   PubMed Web of Science ®Google Scholar
• Amsden JR, Slain D. Antifungal dosing in obesity: a review of the literature. Curr Fungal Infect Rep. 2011;5(2):83–91. doi:10.1007/s12281-011-0049-7
   Google Scholar
• De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61 Suppl 1:27–37. doi:10.2165/00003495-200161001-00003
   PubMed Web of Science ®Google Scholar
• Grant SM, Clissold SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs. 1989;37(3):310–344. doi:10.2165/00003495-198937030-00003
   PubMed Web of Science ®Google Scholar
• Blouin RA, Warren GW. Pharmacokinetic considerations in obesity. J Pharm Sci. 1999;88(1):1–7. doi:10.1021/js980173a
   PubMed Web of Science ®Google Scholar
• Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–231. doi:10.2165/00003088-200039030-00004
   PubMed Web of Science ®Google Scholar
• Hanley MJ, Abernethy DR, Greenblatt DJ. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet. 2010;49(2):71–87. doi:10.2165/11318100-000000000-00000
   PubMed Web of Science ®Google Scholar
• Khurana A, Agarwal A, Agrawal D, Sethia K. Re-emerging role of KOH smear examination in the era of recalcitrant dermatophytoses. Dermatol Ther. 2021;34(2):e14891. doi:10.1111/dth.14891
   PubMed Web of Science ®Google Scholar
• Shenoy MM, Teerthanath S, Karnaker VK, Girisha BS, Krishna Prasad MS, Pinto J. Comparison of potassium hydroxide mount and mycological culture with histopathologic examination using periodic acid-Schiff staining of the nail clippings in the diagnosis of onychomycosis. Indian J Dermatol Venereol Leprol. 2008;74(3):226–229. doi:10.4103/0378-6323.39584
   PubMed Web of Science ®Google Scholar
• Thompson GR, Lewis P, Mudge S, Patterson TF, Burnett BP. Open-label crossover oral bioequivalence pharmacokinetics comparison for a 3-day loading dose regimen and 15-Day Steady-State Administration of SUBA-itraconazole and conventional itraconazole capsules in healthy adults. Antimicrob Agents Chemother. 2020;64(8):e00400–20. doi:10.1128/AAC.00400-20
   PubMed Web of Science ®Google Scholar
• Nield B, Larsen SR, van Hal SJ. Clinical experience with new formulation SUBA®-itraconazole for prophylaxis in patients undergoing stem cell transplantation or treatment for haematological malignancies. J Antimicrob Chemother. 2019;74(10):3049–3055. doi:10.1093/jac/dkz303
   PubMed Web of Science ®Google Scholar
• Lindsay J, Sandaradura I, Wong K, et al. Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. J Antimicrob Chemother. 2017;72(12):3414–3419. doi:10.1093/jac/dkx295
   PubMed Web of Science ®Google Scholar